Dr Thomas Reinard's working group at the Institute of Plant Genetics, Section Plant Biotechnology, has been researching sustainable antibody production processes for some time. With Stas Hans' doctoral thesis, a breakthrough was achieved with the use of diatoms and comprehensive optimisation of the entire process: A complete workflow has now been established that enables a very high yield of antibodies of many formats (such as IgG, scFv-Fc, Fab2).
Environmentally friendly and animal-free: ethical and sustainable diagnostic products
There are many applications for such antibodies, which are usually extracted from the blood of specially bred mice, such as Covid-19 tests or pregnancy tests. The economic potential of moving away from the expensive and animal suffering associated with the previous method of obtaining antibodies was the starting point for the idea of founding the company: In spring 2023, the team from the Institute of Plant Genetics won the start-up competition Startup-Impuls and was able to found the start-up Phaeosynt GmbH in August 2023 thanks to support from the start-up service of Leibniz University Hannover (LUH).
Stas Hans, who studied plant biotechnology and molecular biology, biological-technical assistant Eva-Maria Plönnigs, Dr Maren Wichmann and Dr Thomas Reinard were the main researchers at the institute. Dr Alina Eilers, who graduated in the Life Science degree programme and already worked with rapid tests during her doctorate, and economist Stephanie Pfeil-Coenen have now joined the team with the company spin-off. After initially focusing exclusively on a B2B business model, the start-up is currently focussing on the production of the first vegan pregnancy test, which is expected to be launched in 2025.
Other products are being developed in close collaboration with Reinard's working group. For example, novel secondary antibodies are currently being developed as part of the BMBF project AniSAN. These are also vegan and offer many advantages over the products currently on the market as, unlike animal antibodies, they are permanently available and recognise their antigen more specifically. Although work on the novel secondary antibodies only started in April 2023, there are already interested parties for these novel products, which are of interest to many scientific and medical laboratories.
In this way, students working on their bachelor's, master's or doctoral thesis in the working group come into contact with a commercial application of research and science at an early stage and are therefore ideally prepared for the future.
Good company launch thanks to funding and mentoring in the High-Tech Incubator Biointelligence Lower Saxony (HTI) programme
The start-up Phaeosynt was not only able to score points in start-up competitions - it is also an alumnus of the BioIntelligence programme of the High-Tech Incubator (HTI). Phaeosynt's path from conception to realisation was supported by HTI-BioIntelligence and its advisory board members. Stephanie Pfeil-Coenen (CEO) emphasises: ‘What distinguishes the HTI is its clear focus on biotechnology. We had the pleasure of working with a team of nice people who really care about helping start-ups like ours.’
The BioIntelligence programme bridges the gap from company idea to Proof of Concept (PoC): It offers exclusive network access, professional coaching and mentoring from renowned experts as well as €200,000 in equity-free grants. The programme is funded by the Lower Saxony Ministry of Economic Affairs and is represented at eight locations - in Hanover as the Biointelligence High-Tech Incubator.
- Video feature SAT.1 REGIONAL: Start-up from Hanover invents vegan pregnancy test [German language]
- Start-up Phaeosynt GmbH
- Funded by startup.niedersachsen
